Stocks · News reference
Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est
Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $1.95-$2.29 to $0.76 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $925.000 million-$1.000 billion to $910.000 million vs $945.097
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results.
8-K filing — USANA HEALTH SCIENCES INC (USNA)
Filed: 2026-08-04 AccNo: 0000896264-26-000050 Size: 763 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits